Jacques DUMAS

About

Jacques Dumas joined AdBio Partners in 2025 as a Venture Partner. He has over 30 years of experience in drug discovery and development. He is a co-inventor of two Oncology drugs, Nexavar® and Stivarga®, and played a key role in the registration of Xerava®, a broad-spectrum antibacterial. Jacques has been working with Adbio as a consultant since 2023. He is currently Chief Scientific Officer (CSO) at AiCuris where he oversees non-clinical development. Between 2020 and 2024 Jacques worked at Arrakis, a company dedicated to the discovery of small molecules targeting RNA, first as SVP then CSO. From 2015 to 2019, Jacques was CSO at Tetraphase, a publicly traded company focused on fully synthetic tetracycline antibacterials where he supported the early pipeline and the US/EU eravacycline approvals. Before joining Tetraphase, Jacques was CSO at Idenix (acquired by Merck in 2014) working on liver-targeted nucleosides for the treatment of Hepatitis C. Between 1992 and 2013, Jacques held various R&D roles at AstraZeneca and Bayer, both in Europe and the USA.